Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.42 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SQOR | Q9Y6N5 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16936472 | 0.83 | NPSR1 (0.68) | KMT2ANPSR1MEN1ALDH1A1TDP1 | |
| SCHEMBL12825464 | 0.79 | ALDH1A1 (0.46) | KMT2ANPSR1MEN1L3MBTL1CYP1A2 | |
| SCHEMBL22717337 | 0.75 | KDM4E (0.47) | KMT2ANPSR1MEN1L3MBTL1ALDH1A1 | |
| SCHEMBL16681058 | 0.74 | ALDH1A1 (0.59) | KMT2ANPSR1MEN1L3MBTL1CYP1A2 | |
| SCHEMBL7220037 | 0.74 | ADORA1 (0.49) | KMT2ANPSR1MEN1L3MBTL1CYP1A2 | |
| SCHEMBL27778797 | 0.73 | GABRA1 (0.41) | NPSR1CYP1A2CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL1623647 | 0.72 | L3MBTL1 (0.54) | KMT2ANPSR1MEN1L3MBTL1CYP1A2 | |
| SCHEMBL5218636 | 0.72 | L3MBTL1 (0.71) | KMT2ANPSR1MEN1L3MBTL1CYP1A2 | |
| SCHEMBL22717394 | 0.72 | KCNN4 (0.44) | KMT2ANPSR1MEN1ALDH1A1SQOR | |
| SCHEMBL31350444 | 0.70 | ALDH1A1 (0.68) | KMT2ANPSR1L3MBTL1CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318467-B2 | Inhibitors of GSK-3 and crystal structures of GSK-3β protein and protein complexes | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318467-B2 | Inhibitors of GSK-3 and crystal structures of GSK-3β protein and protein complexes | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318467-B2 | Inhibitors of GSK-3 and crystal structures of GSK-3β protein and protein complexes | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-27 | — | — | US | disclosed |
| US-20110129896-A1 | INHIBITORS OF GSK-3 AND CRYSTAL STRUCTURES OF GSK-3Beta PROTEIN AND PROTEIN COMPLEXES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-02 | — | — | US | disclosed |
| US-20110129896-A1 | INHIBITORS OF GSK-3 AND CRYSTAL STRUCTURES OF GSK-3Beta PROTEIN AND PROTEIN COMPLEXES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-02 | — | — | US | disclosed |
| US-20110129896-A1 | INHIBITORS OF GSK-3 AND CRYSTAL STRUCTURES OF GSK-3Beta PROTEIN AND PROTEIN COMPLEXES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-02 | — | — | US | disclosed |
| EP-2295550-A2 | Crystal structures of GSK-3beta protein and protein complexes and their use. | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-16 | — | — | EP | disclosed |
| US-7883881-B2 | Unphosphorylated glycogen synthase kinase-3-g-beta (GSK) from baculovirus overexpression system; competitive binding; diabetes, Alzheimer's disease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-02-08 | — | — | US | disclosed |
| US-7883881-B2 | Unphosphorylated glycogen synthase kinase-3-g-beta (GSK) from baculovirus overexpression system; competitive binding; diabetes, Alzheimer's disease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-02-08 | — | — | US | disclosed |
| US-7883881-B2 | Unphosphorylated glycogen synthase kinase-3-g-beta (GSK) from baculovirus overexpression system; competitive binding; diabetes, Alzheimer's disease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-02-08 | — | — | US | disclosed |
| US-20080262205-A1 | Inhibitors of GSK-3 and crystal structures of GSK-3beta protein and protein complexes | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080262205-A1 | Inhibitors of GSK-3 and crystal structures of GSK-3beta protein and protein complexes | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080262205-A1 | Inhibitors of GSK-3 and crystal structures of GSK-3beta protein and protein complexes | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-10-23 | — | — | US | disclosed |
| US-7390808-B2 | Inhibitors of GSK-3 and crystal structures of GSK-3β protein and protein complexes | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-06-24 | — | — | US | disclosed |
| US-7390808-B2 | Inhibitors of GSK-3 and crystal structures of GSK-3β protein and protein complexes | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-06-24 | — | — | US | disclosed |
| US-7390808-B2 | Inhibitors of GSK-3 and crystal structures of GSK-3β protein and protein complexes | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-06-24 | — | — | US | disclosed |
| EP-1435957-A4 | INHIBITORS OF GSK-3 AND CRYSTAL STRUCTURES OF GSK-3BETA PROTEIN AND PROTEIN COMPLEXES | VERTEX PHARMA (US) | 2005-04-13 | — | — | EP | disclosed |
| EP-1435957-A2 | INHIBITORS OF GSK-3 AND CRYSTAL STRUCTURES OF GSK-3BETA PROTEIN AND PROTEIN COMPLEXES | Vertex Pharmaceuticals Incorporated (US) | 2004-07-14 | — | — | EP | disclosed |
| US-20030125332-A1 | Inhibitors of GSK-3 and crystal structures of GSK-3 protein and protein complexes | VERTEX PHARMACEUTICALS INCORPORATED | 2003-07-03 | — | — | US | disclosed |
| WO-2002088078-A2 | INHIBITORS OF GSK-3 AND CRYSTAL STRUCTURES OF GSK-3β PROTEIN AND PROTEIN COMPLEXES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125332-A1 | Inhibitors of GSK-3 and crystal structures of GSK-3 protein and protein complexes | GSK3B, GSK3A, GSKIP | KMT2A 2776/4885NPSR1 4636/4885MEN1 2941/4885 |
| US-20080262205-A1 | Inhibitors of GSK-3 and crystal structures of GSK-3beta protein and protein complexes | GSK3B, GSK3A, GSKIP | KMT2A 3265/4885NPSR1 4685/4885MEN1 3259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.